1. Home
  2. HIHO vs BCDA Comparison

HIHO vs BCDA Comparison

Compare HIHO & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highway Holdings Limited

HIHO

Highway Holdings Limited

HOLD

Current Price

$0.82

Market Cap

4.8M

Sector

Industrials

ML Signal

HOLD

BCDA

BioCardia Inc.

HOLD

Current Price

$1.28

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIHO
BCDA
Founded
1990
N/A
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
14.5M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
HIHO
BCDA
Price
$0.82
$1.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
14.0K
72.3K
Earning Date
12-15-2025
11-12-2025
Dividend Yield
14.63%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,143,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$1.00
52 Week High
$2.05
$3.20

Technical Indicators

Market Signals
Indicator
HIHO
BCDA
Relative Strength Index (RSI) 15.86 42.47
Support Level $1.12 $1.23
Resistance Level $1.28 $1.38
Average True Range (ATR) 0.07 0.09
MACD -0.03 -0.02
Stochastic Oscillator 11.76 21.43

Price Performance

Historical Comparison
HIHO
BCDA

About HIHO Highway Holdings Limited

Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: